The present study aimed to characterize in-depht the presence of different promising therapeutic targets (i.e., Cancer Testis Antigens and BRAFV600E) on melanoma cells along with the course of the disease. Data obtained gave the rationale to design novel and potentially more effective therapeutic strategies in melanoma patients
